Alector presents PhII data on lead dementia drug; Chinese oncology biotech nets modest Series A+
Back in June, GSK paid Alector $700 million to kickstart an alliance for rights to two drugs targeting a range of neurological diseases.
The next month, Alector showed via early data that one of the drugs, antibody AL001 for a genetic and rapidly progressing form of dementia, brought levels of progranulin back to near-normal levels after six months in nine patients. Seven stayed at near-normal after a year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
